EMA Application withdrawn: Vibativ (telavancin) — Astellas Pharma Europe B. V.

View source ↗

Summary

EMA withdrew the application for Vibativ (telavancin) by Astellas Pharma Europe B. V.; therapeutic areas include skin infections and staphylococcal soft tissue …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Skin Diseases
• Soft Tissue Infections
• Staphylococcal Infections

Drugs mentioned

• Vibativ (telavancin)

Snippet

Status: Application withdrawn. Therapeutic area: Skin Diseases, Infectious;Staphylococcal Infections;Soft Tissue Infections. MAH: Astellas Pharma Europe B. V.. Decision date: 31/12/2009